Good question.
The P2 GvHD trial is a 60-patient, double blind study with nearly all endpoints at 100 days post-treatment. There are two minor "other outcomes" that are measured at 365 days post-treatment, but all key data will be available to be unblinded at 100 days. Clinicaltrials.gov lists December 2017 as the estimated primary completion date. If you assume that means December 31, and you assume enrollment is on pace to meet that goal (a large assumption, no doubt), then we could reasonably expect a PR regarding completion of enrollment in roughly one month - sometime in mid or late September. Data would obviously not be available until sometime in early 2018.
Wouldn't that be a nice thing to layer on to combo PE's? And remember - many biotech buyouts occur after P2, meaning that potential buyers may see real value in positive P2 results. Not to say that this will be the case here, but it would be naive not to consider the possibility when viewing valuations if a deal were to happen six months from now.
News 
Market Data 
Discover 
